Dabrafenib plus trametinib results in significantly more responses and longer progression-free survival than standard chemotherapy for pediatric patients with low-grade glioma with BRAF V600 mutations, according to a study ...
12 hours ago
0
16
A new research paper titled "Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma" has been published in Oncotarget.
Sep 19, 2023
0
12
Osteochondral defects, often caused by injury or various pathologies, typically lead to the onset of osteoarthritis, and may ultimately result in the comprehensive degradation of the joint and consequent disability. Despite ...
Sep 19, 2023
0
0
A new study has shed light on why immunotherapy does not always work in certain types of cancer. Led by researchers at EMBL's European Bioinformatics Institute (EMBL-EBI), Cold Spring Harbor Laboratory (CSHL), and the Massachusetts ...
Sep 14, 2023
0
25
Concerns about the impact of pharmaceutical agents on fetal development have prompted researchers at Iowa State University to undertake a key study using a placenta-on-a-chip model. The study, focused on the transport of ...
Sep 12, 2023
0
0
A leukemia test can help identify patients who are strong candidates for lifelong treatment free remission (TFR)—meaning they are effectively cured of the disease.
Sep 12, 2023
0
8
Osimertinib plus chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit compared to osimertinib alone, according to research presented at the International Association ...
Sep 11, 2023
0
6
Extended pleurectomy decortication combined with chemotherapy is associated with worse survival outcomes, a higher incidence of serious adverse events, and a diminished quality of life compared to platinum and pemetrexed ...
Sep 11, 2023
0
5
The Taiwan National Lung Cancer Early Detection Program detected 85% of lung cancer cases at either a phase 0 or phase 1 level, demonstrating that lung cancer screening can detect lung cancer at an early enough phase to allow ...
Sep 11, 2023
0
1
The combination of benmelstobart, anlotinib, and chemotherapy demonstrated significant benefits compared to placebo and chemotherapy in terms of median progression-free survival and overall survival for patients with extensive-stage ...
Sep 11, 2023
0
1
